Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prarthana Chatterjee

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Biomolecular Structure & Dynamics|August 10, 2023
Evaluating chemotherapeutic potential of soya-isoflavonoids against high penetrance genes in triple-negative breast cancerPrarthana Chatterjee, Satarupa Banerjee
Scientific Reports|January 6, 2025
A computational and structural approach to identify malignant non-synonymous FOXM1 single nucleotide polymorphisms in triple-negative breast cancerPrarthana Chatterjee, Satarupa Banerjee
Biochemical Pharmacology|October 20, 2023
Unveiling the mechanistic role of the Aryl hydrocarbon receptor in environmentally induced Breast cancerPrarthana Chatterjee, Satarupa Banerjee
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2022
Cancer secretome: finding out hidden messages in extracellular secretionsMrunali Padgaonkar, Saket Shendre, Prarthana Chatterjee, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 29, 2024
Human Pluripotent Stem Cell-Based Assays to Predict Developmental ToxicityMadhura Banerjee, Aritrika Das, Prarthana Chatterjee, et al.
Molecular Biotechnology|February 2, 2023
Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 ReceptorPrarthana Chatterjee, Rohit Karn, I Arnold Emerson, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 20, 2023
Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancerPrarthana Chatterjee, Rohit Karn, Arnold Emerson Isaac, et al.
ACS Omega|July 22, 2024
Deciphering the Chemotherapeutic Role of the Aryl Hydrocarbon Receptor Antagonist Resveratrol against the High-Penetrance Genes of Triple-Negative Breast CancerPrarthana Chatterjee, Rohit Karn, Arnold Emerson I, et al.
Journal of Biomolecular Structure & Dynamics|July 6, 2023
Identification of pseudobaptigenin as a novel polyphenol-based multi-target antagonist of different hormone receptors for breast cancer therapeuticsSarbajit Ray, Suchetana Gupta, Gayatri Panda, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Biomolecular Structure & Dynamics|August 10, 2023
Evaluating chemotherapeutic potential of soya-isoflavonoids against high penetrance genes in triple-negative breast cancerPrarthana Chatterjee, Satarupa Banerjee
Scientific Reports|January 6, 2025
A computational and structural approach to identify malignant non-synonymous FOXM1 single nucleotide polymorphisms in triple-negative breast cancerPrarthana Chatterjee, Satarupa Banerjee
Biochemical Pharmacology|October 20, 2023
Unveiling the mechanistic role of the Aryl hydrocarbon receptor in environmentally induced Breast cancerPrarthana Chatterjee, Satarupa Banerjee
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2022
Cancer secretome: finding out hidden messages in extracellular secretionsMrunali Padgaonkar, Saket Shendre, Prarthana Chatterjee, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 29, 2024
Human Pluripotent Stem Cell-Based Assays to Predict Developmental ToxicityMadhura Banerjee, Aritrika Das, Prarthana Chatterjee, et al.
Molecular Biotechnology|February 2, 2023
Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 ReceptorPrarthana Chatterjee, Rohit Karn, I Arnold Emerson, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 20, 2023
Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancerPrarthana Chatterjee, Rohit Karn, Arnold Emerson Isaac, et al.
ACS Omega|July 22, 2024
Deciphering the Chemotherapeutic Role of the Aryl Hydrocarbon Receptor Antagonist Resveratrol against the High-Penetrance Genes of Triple-Negative Breast CancerPrarthana Chatterjee, Rohit Karn, Arnold Emerson I, et al.
Journal of Biomolecular Structure & Dynamics|July 6, 2023
Identification of pseudobaptigenin as a novel polyphenol-based multi-target antagonist of different hormone receptors for breast cancer therapeuticsSarbajit Ray, Suchetana Gupta, Gayatri Panda, et al.
Pageof 1